Cargando…

High expression of cancer stem cell markers in cholangiolocellular carcinoma

PURPOSE: Cholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwahashi, Shuichi, Utsunomiya, Tohru, Shimada, Mitsuo, Saito, Yu, Morine, Yuji, Imura, Satoru, Ikemoto, Tetsuya, Mori, Hiroki, Hanaoka, Jun, Bando, Yoshimi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651534/
https://www.ncbi.nlm.nih.gov/pubmed/23192764
http://dx.doi.org/10.1007/s00595-012-0437-9
_version_ 1782269229804814336
author Iwahashi, Shuichi
Utsunomiya, Tohru
Shimada, Mitsuo
Saito, Yu
Morine, Yuji
Imura, Satoru
Ikemoto, Tetsuya
Mori, Hiroki
Hanaoka, Jun
Bando, Yoshimi
author_facet Iwahashi, Shuichi
Utsunomiya, Tohru
Shimada, Mitsuo
Saito, Yu
Morine, Yuji
Imura, Satoru
Ikemoto, Tetsuya
Mori, Hiroki
Hanaoka, Jun
Bando, Yoshimi
author_sort Iwahashi, Shuichi
collection PubMed
description PURPOSE: Cholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significance of cancer stem cell markers, including CD133, CD44, and EpCAM, in CLC. METHODS: The subjects of this study were three patients with CLC and one patient with an intermediate type of combined hepatocellular cholangiocarcinoma (CHC). The cancer cell markers, CK7, CK19, and EMA, were evaluated immunohistochemically. RESULTS: Histological examination of the CLC revealed morphologically cholangiolar features and immunohistochemical examination revealed positivity for CD133, CD44, and EpCAM. On the other hand, in the intermediate type of CHC, only CD44 was positive, whereas CD133 and EpCAM were negative. CONCLUSION: CLC may have stronger features derived from HpSCs than an intermediate type of CHC.
format Online
Article
Text
id pubmed-3651534
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Springer Japan
record_format MEDLINE/PubMed
spelling pubmed-36515342013-05-13 High expression of cancer stem cell markers in cholangiolocellular carcinoma Iwahashi, Shuichi Utsunomiya, Tohru Shimada, Mitsuo Saito, Yu Morine, Yuji Imura, Satoru Ikemoto, Tetsuya Mori, Hiroki Hanaoka, Jun Bando, Yoshimi Surg Today Original Article PURPOSE: Cholangiolocellular carcinoma (CLC) is an extremely rare malignant liver tumor. It is thought to originate from the ductules and/or canals of Hering, where hepatic stem cells (HpSC) are located, but there are few reports on cancer stem cell markers in CLC. Thus, we evaluated the significance of cancer stem cell markers, including CD133, CD44, and EpCAM, in CLC. METHODS: The subjects of this study were three patients with CLC and one patient with an intermediate type of combined hepatocellular cholangiocarcinoma (CHC). The cancer cell markers, CK7, CK19, and EMA, were evaluated immunohistochemically. RESULTS: Histological examination of the CLC revealed morphologically cholangiolar features and immunohistochemical examination revealed positivity for CD133, CD44, and EpCAM. On the other hand, in the intermediate type of CHC, only CD44 was positive, whereas CD133 and EpCAM were negative. CONCLUSION: CLC may have stronger features derived from HpSCs than an intermediate type of CHC. Springer Japan 2012-11-29 2013 /pmc/articles/PMC3651534/ /pubmed/23192764 http://dx.doi.org/10.1007/s00595-012-0437-9 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/2.0/ Open AccessThis article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
spellingShingle Original Article
Iwahashi, Shuichi
Utsunomiya, Tohru
Shimada, Mitsuo
Saito, Yu
Morine, Yuji
Imura, Satoru
Ikemoto, Tetsuya
Mori, Hiroki
Hanaoka, Jun
Bando, Yoshimi
High expression of cancer stem cell markers in cholangiolocellular carcinoma
title High expression of cancer stem cell markers in cholangiolocellular carcinoma
title_full High expression of cancer stem cell markers in cholangiolocellular carcinoma
title_fullStr High expression of cancer stem cell markers in cholangiolocellular carcinoma
title_full_unstemmed High expression of cancer stem cell markers in cholangiolocellular carcinoma
title_short High expression of cancer stem cell markers in cholangiolocellular carcinoma
title_sort high expression of cancer stem cell markers in cholangiolocellular carcinoma
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3651534/
https://www.ncbi.nlm.nih.gov/pubmed/23192764
http://dx.doi.org/10.1007/s00595-012-0437-9
work_keys_str_mv AT iwahashishuichi highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT utsunomiyatohru highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT shimadamitsuo highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT saitoyu highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT morineyuji highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT imurasatoru highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT ikemototetsuya highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT morihiroki highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT hanaokajun highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma
AT bandoyoshimi highexpressionofcancerstemcellmarkersincholangiolocellularcarcinoma